GlassScriptPhysician profile
Kathy Deng
NPI 1548571359
$9,696.51
in general payments reported to CMS, 2019-2025
67 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $443 · 2021: $880 · 2022: $1,139 · 2023: $2,899 · 2024: $995 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,976 · Consulting Fee: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.37 |
| Consulting Fee | $1,942.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,282.51 | 2019-2025 | Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $1,189.02 | 2019-2025 | |
| Janssen Biotech, INC. | $546.49 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Gilead Sciences, INC. | $453.14 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $437.85 | 2019-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $386.18 | 2019-2025 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $330.09 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $310.14 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Pfizer INC. | $251.08 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $214.61 | 2019-2025 | Ultomiris |
| Incyte Corporation | $200.21 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genentech USA, INC. | $150.21 | 2019-2025 | Tecentriq, Tecentriq Hybreza, Itovebi |
| Regeneron Healthcare Solutions, INC. | $139.29 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $137.56 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.55 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Deng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.